US2022347466A1PendingUtilityA1

Device for an electrophysiology procedure

Assignee: IONESCU BOGDAN GABRIELPriority: Dec 27, 2018Filed: Dec 20, 2020Published: Nov 3, 2022
Est. expiryDec 27, 2038(~12.4 yrs left)· nominal 20-yr term from priority
A61B 5/318A61B 5/308A61B 5/304A61N 1/37223A61B 5/287A61B 18/1492A61M 2210/125A61B 18/1815A61B 5/6852A61N 1/0565A61N 1/362A61B 2018/00577A61B 2018/00363A61N 1/3621A61N 1/08A61B 2018/00642A61B 18/20A61B 5/363A61N 1/057A61B 2018/00958A61N 2001/058A61B 2018/00904A61B 2018/00827A61B 5/6857A61B 2018/00351A61B 5/361A61B 5/367A61N 1/361A61B 2018/00916A61B 2018/00892A61B 2018/1266A61N 1/056A61B 2018/00357A61N 1/385A61B 18/1206A61B 2018/00839A61B 5/6858
37
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A quantum cardiac electrophysiology device comprising an array of consumable half-ferromagnetic active electrodes connected to an array of semiconductor of half-ferromagnetic selector switches over an array of half-ferromagnetic resistors to a neutral charges out of the heart, by casting and/or inking the arrhythmic substrate of an arrhythmia by the electrophysiology quantum entan- glement of said arrhythmic substrate.

Claims

exact text as granted — not AI-modified
1 . A quantum cardiac electrophysiology device, comprising:
 A consumable active electrodes array, wherein each said consumable electrode may be configured to be half-ferromagnetic;   A first selector switch array ( 156 -array) commutatively connected to the consumable active electrode array, wherein each first selector switch from said first selector switch array is further on configured to be a first magnetic tunnel selector switch wherein said first magnetic tunnel selector switch may be configured to be semiconductor, half-ferromagnetic or both;   A second selector switch array ( 155 -array) commutatively connected to the consumable active electrode array, wherein each second selector switch from said second selector switch array is further on configured to be a second magnetic tunnel selector switch wherein said second magnetic tunnel selector switch may be configured to be semiconductor, half-ferromagnetic or both;   A resistor array ( 151 -array), bijectively connected to said second selector switch array ( 155 -array) wherein said half-ferromagnetic resistors are in anti-parallel state to the heart magnetic field provided by the myocardial band;   A sensor device array ( 160 -array) configured to be bijectively connected to said first selector switch array ( 156 -array).   
     
     
         2 . A method of inking a collapsed arrhythmic substrate wherein said inking is the decay of at least part of at least one consumable active electrodes of  claim 1  selectively connected to at least one said first magnetic tunnel selector switch of  claim 1 , wherein said decay within said collapsed arrhythmic substrate is provided when at least one negative differential resistance (NDR) of at least one biological qubit of said collapsed arrhythmic substrate was measured. 
     
     
         3 . A method of inking a collapsed arrhythmic substrate with a half-ferromagnetic staining ink wherein said half-ferromagnetic staining ink is provided and is delivered from an external can to said collapsed arrhythmic substrate through the internal lumen of a mapping catheter or optionally through the lumen of an additional mapping catheter when at least one negative differential resistance (NDR) of at least one biological qubit of said collapsed arrhythmic substrate was measured. 
     
     
         4 . A method of inking a not yet collapsed arrhythmic substrate with a half-ferromagnetic staining ink, wherein said half-ferromagnetic staining ink is provided and configured to selectively collapse the substrate where at least one negative differential resistance (NDR) of at least one biological qubit of said not yet collapsed substrate is provided as said half-ferromagnetic staining ink applies and is entangled at said not yet collapsed arrhythmic substrate, wherein said half-ferromagnetic staining ink is delivered into the vascular system or into the pericardial space using conventional access points. 
     
     
         5 . The methods of  claims 2 - 4  wherein the inked-in collapsed arrhythmic substrate is a quantum built-in implantable cardiac device, locally entangled within said collapsed arrhythmic substrate and being configured to be programmable by quantum magnetic interference or SQUID devices.

Join the waitlist — get patent alerts

Track US2022347466A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.